|
|
Epicept Corporation - Comparative Business Analysis Snapshot
Business Description
Epicept Corporation. The Group's principal activity is to develop and commercialize pharmaceutical products for the treatment of cancer and pain. The lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. In addition to Ceplene(R), it has two oncology compounds and a pain product candidate for the treatment of peripheral neuropathies in clinical development. Its cancer portfolio includes Crinobulin, or EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors and lymphomas. Its late-stage pain product candidate, EpiCeptTM NP-1 Cream is a prescription topical analgesic cream designed to provide effective long-term relief of pain associated with peripheral neuropathies. It operates in the Unites States and Germany.
Competitor Analysis
This analysis compares Epicept Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
